Orris

Compound A 5 mark answer for anaesthesia exam going student

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Loading Image
Here is a complete, exam-ready 5-mark answer on Compound A for an anaesthesia student:

Compound A

Definition and Formation

Compound A is fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether - a haloalkene (vinyl ether) byproduct produced when sevoflurane undergoes base-catalyzed degradation in the presence of CO2 absorbents (soda lime, Baralyme) within the anaesthetic breathing circuit. Strong bases (KOH, NaOH) extract a proton from sevoflurane's isopropyl group, releasing hydrofluoric acid (HF) and forming Compound A. It is volatile and is absorbed via alveolar gas exchange.

Factors Affecting Compound A Production

FactorEffect
Low fresh gas flow (FGF)Higher Compound A concentration (inversely related to FGF)
Type of absorbentBaralyme > Soda lime; KOH-based > NaOH-based
High vaporizer outputMore sevoflurane available for degradation
Prolonged anaesthesiaGreater cumulative ppm-hour exposure
High temperatureAccelerates degradation reaction
  • At FGF of 1 L/min: ~20 ppm with soda lime, ~30 ppm with Baralyme
  • Modern Ca(OH)2 or LiOH absorbents (KOH/NaOH-free) generate zero or negligible Compound A

Nephrotoxicity: Animal vs. Human

In rats: Compound A causes proximal tubular necrosis at cumulative exposures >150 ppm-hours. Exposure >200 ppm-hours causes reversible damage with elevated BUN and creatinine. Exposure >1000 ppm-hours is lethal in 50% of rats.
In humans: No clinically significant nephrotoxicity has been demonstrated - even at exposures >200 ppm-hours. Standard renal function markers (BUN, creatinine, urinary glucose/protein) and sensitive markers (NAG, AAP, β2-microglobulin) remain normal.

Mechanism of Nephrotoxicity (Rodents)

The pathway is illustrated below:
Compound A nephrotoxicity pathway
Fig. 18.19 - Miller's Anaesthesia 10e: Proposed pathway for Compound A nephrotoxicity in rodents
  1. Sevoflurane → (strong base / CO2 absorbent) → Compound A
  2. Compound A itself is not directly nephrotoxic
  3. Hepatic S-conjugation with glutathione (via glutathione-S-transferase)
  4. Processed by γ-glutamyl transpeptidase and cysteinylglycine dipeptidase → cysteine conjugate
  5. In the kidney, renal β-lyase cleaves the cysteine conjugate → reactive thionoacyl fluoride
  6. This intermediate acylates renal proteins → tubular damage
Why humans are spared: Human kidneys have far lower β-lyase activity than rat kidneys. Alternative proposed mechanisms include reactive sulfoxide formation via CYP3A isozymes (also less active in humans).

Clinical Significance and Safety

  • No threshold exposure causing more than subclinical renal damage has been identified in humans
  • Sevoflurane is safe even in patients with chronic renal insufficiency at low flow rates (Kharasch et al.)
  • Some studies report transient, reversible abnormalities in sensitive markers (not BUN/creatinine) after prolonged low-flow sevoflurane (>330 ppm-hours), but these are not clinically important
  • The US FDA label recommends fresh gas flows ≥2 L/min for sevoflurane, but many contemporary studies confirm safety at lower flows with modern absorbents

How to Minimise Compound A Exposure

  1. Use higher fresh gas flows (reduces circuit accumulation)
  2. Use modern absorbents free of KOH/NaOH (e.g., Amsorb, Drägersorb Free, LiOH-based)
  3. Limit duration and concentration of sevoflurane where possible
  4. Avoid Baralyme (now voluntarily withdrawn from market)
Key exam point: Compound A nephrotoxicity is a rat phenomenon - it is not clinically relevant in humans due to low renal β-lyase activity. Sevoflurane remains safe for clinical use including in renal disease patients.
(Source: Miller's Anaesthesia, 10e, Chapter 18 - "Sevoflurane, Compound A, and Renal Toxicity")
This is a shared conversation. Sign in to Orris to start your own chat.